undamentalytics Newsletter
Sign in

Ultragenyx Pharmaceutical Inc. cash flow statement

In fiscal 2025, Ultragenyx Pharmaceutical Inc.'s operations generated −$466m of cash; it spent $6.0m on capital projects, leaving free cash flow of −$472m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−161−254−291−345−132−339−380−475−414−466−485
Depreciation and amortisation3620912131826363533
Stock-based pay4868808286105130135158153109
Capital spending103425447311644764
Free cash flow−171−257−295−370−176−412−497−519−421−472−489
Free cash flow after stock pay−219−325−375−452−262−517−627−654−579−625−598
Shares issued——27133043600————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NRIX vs RAREARWR vs RARERARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ultragenyx Pharmaceutical Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ultragenyx Pharmaceutical Inc.